Catalent embarks on $230M viral vector expansion project at Harmans campus

CDMO Catalent is to spend $230 million on adding three further commercial-scale viral vector manufacturing suites and associated support facilities and services at its gene therapy campus in Harmans, Maryland.

The company has cited growing customer demand as the impetus behind this latest investment.

The Harmans campus includes a fully operational FDA- and EMA-approved facility comprising 10 commercial-scale manufacturing suites.

A second facility, which is already under construction following an initial $130 million investment by Catalent in 2020, will add five new manufacturing suites. These are expected to be operational mid-2022.

The latest investment will see the company construct three additional multiroom commercial suites, and expand the site’s storage capabilities for just-in-time inventory space, ultra-low temperature freezers and its water-for-injection infrastructure.

When complete at the end of 2022, the campus will house a total of 18 cGMP viral vector manufacturing suites, each designed to accommodate multiple bioreactors up to 2,000-L and enable the execution of commercial manufacturing from cell bank to purified drug substance.

Furthermore, the expansion will create more than 700 new technical, scientific, and operational employment positions during the next 6 years.

ABOUT CATALENT PHARMA SOLUTIONS

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has the proven expertise, superior technologies and flexible solutions at the right scale to help ensure successful product development, launch, tech transfer and global reliable supply. Our team of nearly 13,000, including approximately 2,400 scientists at over 35 sites, develops more than 700 projects and helps launch over 200 products every year. We produce +72 billion doses of +7,000 products for more than 1,000 customers – or 1 in 20 doses taken by patients globally. We partner with 87 of the top 100 global pharmaceutical marketers, to 24 of 25 biological marketers, to 21 of 25 leading consumer health marketers, to thousands of small innovators globally. Our passion is to help unlock the full potential of your product.